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Abstract
The time of initiation of antiretroviral therapy in HIV-1 infected patients has a determinant effect on the viral dynamics. The
question is, how far can the therapy be delayed? Is sooner always better? We resort to clinical data and to microsimulations
to forecast the dynamics of the viral load at therapy interruption after prolonged antiretroviral treatment. A computational
model previously evaluated, produces results that are statistically adherent to clinical data. In addition, it allows a finer grain
analysis of the impact of the therapy initiation point to the disease course. We find a swift increase of the viral density as a
function of the time of initiation of the therapy measured when the therapy is stopped. In particular there is a critical time
delay with respect to the infection instant beyond which the therapy does not affect the viral rebound. Initiation of the
treatment is beneficial because it can down-regulate the immune activation, hence limiting viral replication and spread.
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Introduction
According to an estimation, the AIDS pandemic has killed
about 2.1 million people, including 330,000 children and about
33.2 million people lived with the disease worldwide [1].
Notwithstanding the exceptional scientific effort to find a ultimate
cure to this immune deficiency disease, there is no definite
treatment to eradicate the virus from infected people to date. What
has been achieved up to date is a prolonged life expectancy by
using antiretroviral cocktails (highly active antiretroviral therapy,
shortly HAART) that, unfortunately, have to be administrated
throughout the life of the patients. Since the uptake of these
therapeutic agents in forms of pills is a significant burden both in
terms of patients commitment and health care costs, there is a
huge interest in understanding when is the golden moment to
initiate the therapy. The question is whether it is possible to delay
the initiation of the therapy while the potency of the immune
response remains unaffected or, conversely, is sooner always better for
anti retro-viral therapy? This issue still remains a challenge although
recent studies agree that an early initiation of the therapy can
influence positively the course of the disease [2]. Hereafter we
show that this is indeed our same conclusion by comparing clinical
data with computer simulations. Moreover, while current
antiretroviral therapy is efficacious only if applied with continuity,
it is of utter interest to study its effect on the dynamics of the virus;
by simulating on a computer the infection, before, during and after
the therapy, we can get insights otherwise difficult or even
impossible to be deduced in vivo.
The early immune response to HIV-1 infection looks likely to be
an important factor in determining the clinical course of disease. If
we watch the first weeks following HIV-1 invasion we find that
they are extremely dynamic. We learn that they are associated
with a hasty damage to the generative immune cell micro-
environment and with an immune response that is only partially
able to control the virus. Once inside the host body, the virus first
replicates locally in the mucosa and then is transported to draining
lymph nodes. There, further viral amplification occurs. In this
initial phase the plasma viremia increases exponentially and
reaches a peak. It terminates when systemic viral dissemination
begins [2]. This phase is associated with significant depletion of
mucosal CD4zT cells. At around the peak time, the disease may
become symptomatic and, more importantly, reservoirs of latent
virus are established [3]. Following this initial ‘‘acute phase’’,
lasting approximatively 100 days after the infection, the beginning
of the chronic phase is characterized by a plateau in the plasma
viral load.
The acute phase is generally divided in the very-early and early
phases. The very-early is asymptomatic, whereas the early is
characterized by the appearance of clinical symptoms [4].
Unsurprisingly, quite a number of researchers has pointed to the
early infection period around the peaking of viremia, prior to
massive CD4z T cell destruction and the establishment of viral
reservoirs, as a narrow but crucial period in which the
antiretroviral therapy can secure a certain advantage on the virus,
controlling its replication, preventing extensive CD4z T cell
depletion from occurring, and curbing generalized immune
activation [2,3]. Hence, there is a ‘‘window of opportunity’’ to
identify. Animal models of AIDS would provide a workbench to
study this issue. However, the only animals susceptible to
experimental HIV-1 (or HIV-2) infection are the chimpanzee,
macaques, gibbon apes and rabbit but unfortunately for us (not
them), AIDS-like disease has not yet been reported in these
species. For what concerns the HIV-infected SCID-hu mice, it is
not yet clear how suitable will it be as a model for AIDS. Another
possibility is to study one of the several subfamilies of naturally
occurring retroviruses that cause immune suppression. For
example the feline immunodeficiency virus (FIV) infecting cats
and the lentivirus simian immunodeficiency virus (SIV) infecting
macaques appear to bear the closest similarity in their pathogen-
esis to HIV infection and AIDS [5]. In either case, leaving out
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tation is its cost, both in terms of time and money. Here is where
computational models come handy. They try to resemble, in the
most realistic yet parsimonious way, the events taking place during
the infection of a virus.
In the present work we check out whether the effect of a timely
HAART initiation can prevent the virus to damage the host
defenses and to lodge in cellular and anatomical reservoirs thus
assuring the patient a nearly regular life. We do this by analyzing
clinical data and simulations performed with a model of HIV-1
infection that has previously shown to be a valuable tool for the
study of the AIDS progression and treatment [6,7]. The computer
simulation allows a finer grain study than clinical data does.
Results and Discussion
For the current study we analyze virological data from HIV
patients treated during the very-early, early and late phase of infection
and compare them with computer simulations. Clinical data were
collected at the National Institute for Infectious Disease ‘‘L.
Spallanzani’’. We classify a total of 54 patients in three groups
according to the time they initiated the therapy. Eleven patients
initiated HAART within 20 days from diagnosis, during the very-
early phase of infection, before symptoms begin. Twenty-two
patients underwent HAART during the early phase of HIV-1
infection. Twenty-one patients started HAART during the chronic
phase of infection thus in the late phase. All patients underwent a
therapy cycle for about a year.
Statistical analysis of the clinical data of the three groups reveals
that there is no difference in viral rebound between early and late
patients (P§0.05, Mann-Whitney U two-tailed test) whereas we
find a difference between very-early and late (Pv0.05, Mann-
Whitney U two-tailed test). Simulations are in line with this
finding. This is shown in Figure 1 that compares a single
simulation of the untreated case with respectively a very-early, early
and late settings. As a first observation, in agreement with clinical
data, we note that as soon as the therapy stops the simulated
viremia readily increases and peaks very much like in the acute
phase of the untreated case. Even more interesting is to notice the
swift viral rebound at therapy discontinuation in the early and late
cases. Instead, there is quite a long delay (*8 weeks) in the very-
early case (cyan area in Figure 1). The gist of the message is that a
delay in the initiation of therapy may give the virus the chance to
damage to the generative immune cell micro-environment and
establish latent virus reservoirs [2,3]. Therefore, despite the fact
that the virus emerges again at therapy discontinuation regardless
of when the therapy started, its early control influences positively
the clinical course of the disease.
Since there is no statistical difference between the early and late
groups, from now on, we concentrate on the analysis of the gap
between the very-early and late groups only. To this purpose we can
safely focus on the time point of 4 weeks after therapy
discontinuation, hereafter indicated by V4~Vt izTz4 ðÞ , where
ti is the time of initiation of the therapy in weeks and T is its
duration.
Before using the simulation to predict the relationship between
the initiation of the therapy and the viremia at its discontinuation,
we have to assess its adherence to clinical data. To this purpose we
carry out a statistical test (chi-square goodness of fit test [23]) and find
that with a significance level of more than 90% the simulations are
adherent to clinical data. Furthermore, in Figure 2, panels A, B
and C, graphically compare the clinical and simulated V4 for both
very-early and late settings. In particular, in panel B the ‘‘whiskers’’
indicate that the median of simulated and real values are pretty
close, whereas panel C shows that the cumulative distribution
functions for the two groups overlap quite well.
The use of the statistical parametric test to evaluate the
relationship between the initiation of the therapy and the
virological rebound V4 urges to check whether the distribution
of the simulated V4 in very-early and late, can be fitted by a normal
distribution. To this purpose panel D of Figure 2 shows the
quantile-quantile plots of the four data sets; data aligned on a line
demonstrates adherence to the normal distribution. Besides, we
perform a chi-square goodness of fit test [23] and find that with a
P{value§0:05 both simulated very-early and late V4 data are
normally distributed. Finally we use a chi-square test for independence
Figure 1. Simulations of treated and untreated case. Comparing simulations of the treated and untreated cases. All simulations share the same
parameter settings with the only difference that therapy starts at day 0 in the very-early, at day 40 in the early and at day 200 in the late settings. The
duration of simulated therapy is one year.
doi:10.1371/journal.pone.0015294.g001
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viral rebound at discontinuation V4 strongly correlates with the
therapy initiation instant ti (x2~191:2).
All the above statistical analysis allow to use the simulation as a
surrogate of reality and therefore to investigate whether there is a
significant association between ti and the viral rebound. The sample
data is summarized in the contingency Table 1. Performing the test we
find x2~191:2. The high value of the statistics leads to the conclusion
that, within a reasonable significance level, the viral rebound at
discontinuation strongly correlates with the therapy initiation instant.
We aim at providing a more precise estimate of the time ‘‘limit’’
beyond which the benefit of an early initiation of therapy vanishes.
The results are shown in Figure 3. The virological rebound at one,
two, four and eight weeks after therapy interruption (called
respectively V1,V2,V4 and V8) as a function of ti are presented.
The points in Figure 3 are fitted pretty well a generalized
(Richards’, [24]) logistic function describing the growth of viremia
as a function of ti,
Vt i ðÞ ~az
k{a
1ze
{dt i{tc ðÞ
, ð1Þ
where the parameter k is the carrying capacity or the upper
asymptote, a is the lower asymptote, d is the growth rate, and tc is
the time of maximum growth.
We observe that there are two regimes, one for tivtc days and
one for tiwtc corresponding to what clinicians call respectively best
controllers (with undetectable HIV RNA levels) and rebounders (whose
Figure 2. Clinical and simulated data. Statistical summary of clinical and simulated V4 for both very-early and late settings. Panel A shows how
the data is distributed. In panel B the ‘‘whiskers’’ indicate the lower, median and upper quartile while largest and smaller values are shown by dashed
lines. Outliers are shown as small circles. Panel C shows the cumulative distribution functions for the two groups. Panel D reports the normal
probability plots (or quantile-quantile plots) for comparison to normal distributions. Legend: SVE = simulated very early, PzVE = patients very early;
SL = simulated late, PzL = patients late.
doi:10.1371/journal.pone.0015294.g002
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level). Therefore tc can be seen as a critical time point beyond
which the benefit of an early initiation of therapy vanishes.
By moving the time of the measurements beyond one week after
therapy interruption (i.e., V2?V4?V8), the resulting fit
corresponds to a greater a, a smaller d and a lower tc. Note in
particular that the limit
lim
d?0
Vt i ðÞ ~ azk ðÞ =2
may lead to the deceiving conclusion that there is no window of
opportunity because the viral rebound is independent from ti.
However, from the test performed on V4 we know that this is not
the case. Along the same line, we note that tc depends on when the
viremia is measured: the estimated tc is equal to about 24, 22, 18
and 9 days respectively for V1,V2,V4 and V8.
Conclusions
HAART is costly, it is demanding for both patient and health
care provider, and it brings quite frequently to adverse effects. The
clinical benefit of treatment must therefore be weighed against the
burden imposed by therapy and its side-effects. In the present
study, we resort to a computer model to forecast the dynamics of
the plasma viral load after prolonged treatment interruption and
compare the results with clinical data. Our conclusion, in line with
literature data, is that very early initiation of the treatment is
beneficial because it can down-regulate the immune activation,
hence limiting viral replication and spread. Interestingly, this view
is supported by the observation that HIV triggers the immune
activation directly (e.g., HIV gene products can induce the
activation of lymphocytes and macrophages as well as the
production of pro-inflammatory cytokines and chemokines [3])
or indirectly (e.g., sustained antigen-mediated immune activation
occurs in HIV-1-infected patients due also to other viruses like the
cytomegalovirus or the Epstein-Barr virus [3]). In both case, the
result is a high level of pro-inflammatory cytokines, such as tumor
necrosis factor alpha, interleukin 6 and interleukin 1 beta, right
from the early stages of HIV-1 infection [3].
Simulations and statistical analysis allow to dig into clinical data
to provide a clear cut evidence of the impact of the therapy
initiation point to the disease course.
Methods
The computational model
The microscopic simulation model we employ has a long
history. It is perhaps one of the oldest computational models of the
immune system, dating back to the early nineties [8]. The current
version [9] we use derives from that early model and has been
specialized to simulate the HIV-1 infection some time ago [6]. In
[10] we have described how the HIV evades immune surveillance
by mutation; in [7] we have shown that early application of
HAART is more likely to be beneficial than the deferred one. We
have also used this model coupled with genetic algorithms to
determine the best therapy interruption protocol [11]. This same
model has also been used to describe other disease courses: in [12]
we have shown that the Epstein-Barr virus cannot be cleared by
the immune system because it exploits reservoirs; in [13,14] we
have modeled the effects of a cancer immunoprevention vaccine.
The utility of this model is that with the greatest fidelity possible,
yet avoiding to end up with an unmanageable model, it represents
the basic facts of the immune action solicited by an infectious
agent. For this reason, every lesson learned in previous studies
including parameter tunings, has become an integral part of the
model itself. Mechanisms like hypermutation, affinity maturation
Table 1. Contingency table.
Viral Late Very early Total
rebound (pz) (pz) (pz)
ƒ36 9 8 104
3–4 19 98 117
§47 4 2 76
Total 99 198 297
Contingency table for simulated data where the expected frequency count for
each cell of the table is at least 5. The rows represent the average viremia after 4
weeks from treatment interruption in logarithmic scale. The columns represent
the two groups in which HAART starts during chronic phase (late) or within the
first 20 days (very-early). The null hypothesis states that knowing the start
timing does not help to predict V4. That is, the events are independent.
Support for the alternative hypothesis suggests that the two events are related.
The value found x2~191:2 rejects the null hypothesis.
doi:10.1371/journal.pone.0015294.t001
Figure 3. Virological rebound after stopping HAART. Virological rebound at 1, 2, 4 and 8 weeks after therapy interruption for different starting
time points of HAART (ti). Dots represent the results of thousands simulations. The fitting lines are given by the Richards’ curve in equation 1.
Standard deviation is about 0.1 log10 copies=ml ðÞ for all points.
doi:10.1371/journal.pone.0015294.g003
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tations have now ‘‘crystallized’’ into the core model.
The simulator represents immunological cells and molecules as
discrete entities residing and interacting on a three-dimensional
regular lattice. Each lattice point represents a unit of volume, that
is, a voxel. The simulated total volume corresponds to a fraction of
a lymph node (see Figure 4). As in cellular automata models, time
is discrete and the state of a lattice point at time t is a function of a
finite number of variables, namely the biological entities residing
on that voxel. Agents are cells and molecules with specific
characteristics (i.e., molecular receptors, half life, etc.). At any time
each agent can be in one of a set of possible states (naı ¨ve, active,
resting, duplicating, etc.). Probabilistic rules define the biological
processes by modifying the state of the entities. We can write
sx ;tz1 ðÞ ~fsx ;t ðÞ ðÞ where sx ;t ðÞ is the state of the voxel x given
as the union of the microstates of all entities in x, that is,
sx ;t ðÞ ~
S
z ez t ðÞ , with the index z running on all entity types and
ez t ðÞrepresenting the value at time t of the attributes of entity type
z. The function fx ;t ðÞ embeds many biological processes like cell
differentiation, cell interaction and movement. Another charac-
teristic of this model is that all molecules and cells’ binding sites (e.g.,
cell receptors) are modeled as binary strings of finite length.
Models of this kind are called binary-string models [15]. Each
interaction requires cell entities to be in a specific state. Once this
condition is fulfilled, the interaction probability is computed as a
function of the distance between receptors. Small molecules (i.e.,
molecules with small molecular weight like interleukins or chemokines
that are carriers of physiological signals, are represented as
concentrations and thus their dynamics can be described by partial
differential equations of the parabolic type
Lc
Lt
~D+2c{lczsx ,t ðÞ
where c~cx ,t ðÞ is the concentration of chemokines, sx ,t ðÞ is the
source term (e.g., activated macrophages), D is the diffusion
Figure 4. Simulation space. The ellipsoid lattice resemble the typical shape of a lymph node. Entities interact within voxels. Typical simulations
consist of 5 ml of volume discretized on 27 voxels and populated by about 2:104 cells.
doi:10.1371/journal.pone.0015294.g004
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the mobility of the cells is taken into account by implementing a
biased random walk that considers experimentally estimated
diffusion coefficients [18,19]. These are the main features. The
interested reader may look at more comprehensive publications for
further details [6,7,20] and in the supplementary materials.
Clinical studies
We analyze the results of clinical studies performed at the
Clinical Department of the National Institute for Infectious
Disease ‘‘L. Spallanzani’’ in Rome.
A first group of eleven patients (9 male and 2 female) were
diagnosed HIV-1 positive between year 1998 and 2006. All
patients initiated HAART within 18 days from diagnosis, during
the very early phase of infection. The very early phase was defined
as having a negative or indeterminate western blot for HIV-1
antibodies in combination with a positive test for either p24
antigen or a detectable HIV-1 RNA concentration. Those patients
were treated with zidovudine/lamivudine (CBV) in combination
with either the reverse transcriptase inhibitor efavirenz (EFZ) or
one protease inhibitor lopinavir/ritonavir (KAL) or indinavir
(IDV). Because of anaemia and neutropenia were diagnosed, in
two cases CBV has been substituted with lamivudine (3TC) and
staduvine (D4T).
The second group consists of twenty-one patients (12 male, 9
female) enrolled in the program between year 1990 and 2004.
They started HAART during the chronic phase of infection
defined as suggested by the guidelines [21].
The third group is made up by twenty-two patients (21 male
and 1 female) enrolled in the program between year 1998 and
2005. Patients in this group underwent HAART during the early
phase of HIV-1 infection. Early patients were defined as having
documented seronegative HIV-1 antibody test within the previous
6 months; acute symptomatic seroconversion illness; evolving
HIV-specific antibody response by ELISA; positive HIV-DNA
PCR in PBMC. Those patients were treated with three different
drugs (in the majority of cases zidovudine (AZT) plus 3TC plus a
protease inhibitor. Further details can be found in table 1 of [22].
All patients underwent a therapy cycle for about a year.
All clinical investigation have been conducted according to the
principles expressed in the Declaration of Helsinki. The Ethical
Committee of the ‘‘L. Spallanzani’’ Institute approved the study
and the patients gave a written informed consent.
Plasma HIV-1 determination
Plasma HIV-1 RNA levels were determined by a second-
generation assay based on nucleic acid sequence based amplifica-
tion (NASBA), for samples collected until 2001 and by the
branched-chain DNA assay (Versant HIV RNA test, Version 3.0,
lower limit of quantification 50 copies/ml; Bayer Diagnostics,
Milan, Italy) from 2001 until 2008.
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